Market
Where will Lenacapavir launch first by end of 2025?
2
Resolution / Starting Odds
North America • 25%
Europe • 25%
Africa • 25%
Asia • 25%
Gilead's official announcements and press releases
Story
Global Leaders Back Lenacapavir, Gilead's HIV Drug with 100% Efficacy in Phase 3 Testing, Single Shot Every Year
Dec 15, 2024, 03:44 PM
Global leaders are uniting to support the development of an injectable medication aimed at eradicating HIV. Gilead Sciences announced plans to initiate Phase 3 testing for Lenacapavir, a drug that could potentially prevent HIV infection with just a single annual injection. This medication has been recognized as a significant scientific advancement, with reports highlighting its remarkable efficacy. A large trial conducted in June involving African adolescent girls and young women demonstrated that the treatment reduced HIV infections to zero, achieving an efficacy rate of 100%. This finding was corroborated by a subsequent trial conducted across multiple regions three months later, reinforcing the drug's potential impact in the fight against HIV/AIDS.
View original story
Similar markets
Southeast Asia • 25%
Other • 25%
Sub-Saharan Africa • 25%
South America • 25%
Asia • 25%
Africa • 25%
Europe • 25%
North America • 25%
United States • 25%
South Africa • 25%
Other • 25%
European Union • 25%
South Africa • 25%
India • 25%
United States • 25%
Other • 25%
Other • 25%
USA • 25%
UK • 25%
South Africa • 25%
Africa • 25%
European Union • 25%
United States • 25%
Other • 25%
Latin America • 25%
Southeast Asia • 25%
South Asia • 25%
Sub-Saharan Africa • 25%
Clinics • 25%
Hospitals • 25%
Community health programs • 25%
Pharmacies • 25%